{
    "clinical_study": {
        "@rank": "112558", 
        "acronym": "EVADO", 
        "arm_group": [
            {
                "arm_group_label": "EVADO", 
                "arm_group_type": "Experimental", 
                "description": "The E.V.A.D.O. system is made of the following components:\nThe ADMIRAL oxygenator, that requires low priming volumes (, has a limited contact surface and contains an accessory independent cardiotomy reservoir, allowing separation of pericardial suction blood.\nThe HARMONY Smart Suction System, which allows automatic regulation of a pumpless extracavity blood sucker, whose rates and pressures depend on whether suction is required for blood/air surfaces (skimming), or for fluids (pooled).\nPaediatric circuits with 3/8\" tubing for both arterial and venous lines."
            }, 
            {
                "arm_group_label": "Conventional CPB", 
                "arm_group_type": "Active Comparator", 
                "description": "conventional cardiopulmonary by-pass (CPB) system"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to assess the effects of the use of EVADO with respect\n      to a conventional cardio-pulmonary bypass (CBP) system on surgical morbidity and mortality.\n      As secondary aim this study wants to conduct appropriate laboratory investigations in order\n      to detect the major biological mechanisms potentially responsible for the beneficial effects\n      of the EVADO system on the coagulation cascade and inflammatory activation."
        }, 
        "brief_title": "Effects on Organ Damage and Surgical Outcome of a New Cardiopulmonary Pass System (EVADO)", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "C.Surgical Procedure; Cardiac", 
        "detailed_description": {
            "textblock": "The present study is designed as a prospective, multicentre, randomized, open label,\n      controlled, 2-arm parallel group, superiority trial.\n\n      Participating centres are selected based on previous experience with the use of the EVADO\n      system.\n\n      Patients elected to open heart surgery for a variety of cardiac conditions related to\n      coronary, valvular or aortic disease or their combination in the participating centers will\n      be screened.\n\n      This study as secondary aim wants to confirm the results of earlier investigation by a\n      multicentre trial conducted on a larger population of patients undergoing a wide spectrum of\n      open heart cardiac operations and either assess a number of cost-efficacy-efficiency\n      indicators."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        patients elected to undergo open heart surgery for a variety of cardiac conditions related\n        to coronary, valvular or aortic disease or their combination and fulfilling the following\n        additional criteria:\n\n          -  Written informed consent\n\n          -  Age 18-85 years\n\n        Exclusion Criteria:\n\n          -  Severe renal or liver failure\n\n          -  Uncompensated diabetes\n\n          -  Autoimmune disease requiring immunosuppressant therapy\n\n          -  Coagulation disorders\n\n          -  Emergent or redo surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805466", 
            "org_study_id": "GR-2009-1591573"
        }, 
        "intervention": [
            {
                "arm_group_label": "EVADO", 
                "description": "EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.", 
                "intervention_name": "EVADO", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Conventional CPB", 
                "description": "conventional miniature cardiopulmonary bypass technique", 
                "intervention_name": "Conventional CPB", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Extracorporeal Vacuum Assisted Device Optimised (EVADO)", 
        "lastchanged_date": "February 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy"
                    }, 
                    "name": "Anthea Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cotignola", 
                        "country": "Italy", 
                        "zip": "48010"
                    }, 
                    "name": "Maria Cecilia Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lecce", 
                        "country": "Italy"
                    }, 
                    "name": "Citt\u00e0 di Lecce Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rapallo", 
                        "country": "Italy"
                    }, 
                    "name": "ICLAS Rapallo"
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A New Cardiopulmonary By-pass System That Minimizes Haemodilution, Hemolysis and Systemic Inflammation. Effects on Organ Damage and Surgical Outcome", 
        "other_outcome": [
            {
                "description": "\u2022 Total duration of hospital admission [Time Frame: participants will be followed for the duration of hospital stay, an expected average of 2 weeks] [Designated as safety issue: Yes]", 
                "measure": "Other pre-specified outcome measures", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "\u2022 Duration of ICU stay", 
                "measure": "Other pre-specified outcome measures", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "\u2022 Time to extubation", 
                "measure": "Other pre-specified outcome measures", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "\u2022 Total postoperative blood loss and blood transfusion volume", 
                "measure": "Other pre-specified outcome measures", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "\u2022 Total hospitalization costs", 
                "measure": "Other pre-specified outcome measures", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "\u2022 Cost-efficiency assessment", 
                "measure": "Other pre-specified outcome measures", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "IRCCS San Raffaele Pisana", 
            "last_name": "Giuseppe Nasso, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint is the composite of in\u2014hospital mortality, defined as death of any cause occurring before hospital discharge, myocardial infarction, stroke; severe renal failure; severe liver failure; severe cardio-respiratory failure; multiorgan failure; need for left ventricular support device; need for dialysis or ultrafiltration: post-operative bleeding; atrial fibrillation.", 
            "measure": "composite of in-hospital mortality and clinical and outcome parameters recorded in the post-operative period", 
            "safety_issue": "Yes", 
            "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805466"
        }, 
        "responsible_party": {
            "investigator_affiliation": "IRCCS San Raffaele", 
            "investigator_full_name": "Giuseppe Nasso, MD", 
            "investigator_title": "Study Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "outcome parameters recorded in the postoperative period: Myocardial infarction", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nStroke", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nSevere renal failure (greater than 2-fold increase in creatinine levels)", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nMultiorgan failure (MOF)", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nNeed for left ventricular support device (IABCP or similar)", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nNeed for dialysis or ultrafiltration", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nPostoperative bleeding", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nAtrial fibrillation", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nSevere liver failure (greater than 2-fold increase in  AST (aspartate aminotransferase), ALT (alanine aminotransferase) and y-GT (y-glutamyltransferase) levels)", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "outcome parameters recorded in the postoperative period:\nSevere cardio-respiratory failure", 
                "measure": "Individual components of the primary end-point", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }
        ], 
        "source": "IRCCS San Raffaele", 
        "sponsors": {
            "collaborator": {
                "agency": "Ettore Sansavini Health Science Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "IRCCS San Raffaele", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}